The goal in demanding the introduction of the mechanism was that multiple companies would immediately trigger independent reviews with US Government support, draw attention to problems in decision-making, essentially overwhelm the system, and force further reform discussions. None of this happened, the US Government quickly lost confidence in the industry, and the Australian Government more successfully leveraged the agreement outcome.
Why the failure of a hard-won process reveals so much about an intractable problem
January 16, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News -
Australian partnership advances gene therapy for Retinitis Pigmentosa
July 15, 2026 - - Latest News -
Patients move to reclaim access agenda ahead of sector negotiations
July 15, 2026 - - Latest News -
An opportunity to become a global destination for paediatric oncology trials
July 15, 2026 - - Latest News

